Paige W Wolstencroft1, David F Fiorentino2. 1. Department of Dermatology, Stanford University School of Medicine, 450 Broadway Street, Redwood City, CA, 94063, USA. 2. Department of Dermatology, Stanford University School of Medicine, 450 Broadway Street, Redwood City, CA, 94063, USA. fiorentino@stanford.edu.
Abstract
PURPOSE OF REVIEW: Dermatomyositis is an idiopathic inflammatory myopathy with a variety of systemic and cutaneous manifestations. The myositis-specific autoantibodies (MSAs) are associated with phenotypic features and provide a tool for sub-classification of dermatomyositis patients. This review focuses on recent work characterizing the clinical features that accompany the MSAs in dermatomyositis. RECENT FINDINGS: There is increasing recognition of the distinct clinical and pathological phenotypes associated with each MSA. Most of these features display considerable overlap between MSA groups. Despite this, there are notable differences between the typical combinations of cutaneous and systemic manifestations, response to therapy, prognosis, and disease sequelae that define each dermatomyositis MSA group. The MSAs may ultimately improve diagnosis and sub-classification of dermatomyositis patients. However, more work is needed to understand the pathologic basis for much of the heterogeneity found within these subgroups.
PURPOSE OF REVIEW: Dermatomyositis is an idiopathic inflammatory myopathy with a variety of systemic and cutaneous manifestations. The myositis-specific autoantibodies (MSAs) are associated with phenotypic features and provide a tool for sub-classification of dermatomyositispatients. This review focuses on recent work characterizing the clinical features that accompany the MSAs in dermatomyositis. RECENT FINDINGS: There is increasing recognition of the distinct clinical and pathological phenotypes associated with each MSA. Most of these features display considerable overlap between MSA groups. Despite this, there are notable differences between the typical combinations of cutaneous and systemic manifestations, response to therapy, prognosis, and disease sequelae that define each dermatomyositis MSA group. The MSAs may ultimately improve diagnosis and sub-classification of dermatomyositispatients. However, more work is needed to understand the pathologic basis for much of the heterogeneity found within these subgroups.
Authors: Jacob T Cox; David M Gullotti; Christopher A Mecoli; Arash H Lahouti; Jemima Albayda; Julie Paik; Cheilonda Johnson; Sonye K Danoff; Andrew L Mammen; Lisa Christopher-Stine Journal: Clin Rheumatol Date: 2017-04-07 Impact factor: 2.980
Authors: Ejaz A Shamim; Lisa G Rider; Janardan P Pandey; Terrance P O'Hanlon; Luis J Jara; Eduardo A Samayoa; Ruben Burgos-Vargas; Janitzia Vazquez-Mellado; Jorge Alcocer-Varela; Mario Salazar-Paramo; Abraham Garcia Kutzbach; James D Malley; Ira N Targoff; Ignacio Garcia-De la Torre; Frederick W Miller Journal: Arthritis Rheum Date: 2002-07
Authors: I Marie; E Hachulla; P Chérin; S Dominique; P-Y Hatron; M-F Hellot; B Devulder; S Herson; H Levesque; H Courtois Journal: Arthritis Rheum Date: 2002-12-15
Authors: Sang Wan Chung; In Seol Yoo; Jinhyun Kim; Seong Wook Kang; Mihye Kwon; Chung Il Joung; In Ah Choi; Sung Hae Chang; Mi Il Kang; Seung Jae Hong; Yeon Ah Lee Journal: Yonsei Med J Date: 2021-05 Impact factor: 2.759
Authors: Mithu Maheswaranathan; Andrew Johannemann; Jason J Weiner; Ryan Jessee; Amanda M Eudy; Lisa Criscione-Schreiber Journal: Clin Rheumatol Date: 2021-02-24 Impact factor: 2.980